NCT00554086CompletedPhase 2
Phase 2 Trial of Maximum Androgen Blockade (MAB) Dose Escalation From 50 mg to 150 mg Bicalutamide (Casodex) for Biochemical Failure in Prostate Cancer Patients
Canadian Urology Research Consortium2 sites in 1 country65 target enrollmentStarted: November 1, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 65
- Locations
- 2
- Primary Endpoint
- Doubling of PSA
Study Overview
Brief Summary
Multi-centre one year trial for patients who have rising PSA while on Casodex 50mg daily dose. Casodex dosage escalated to 150 mg tablet daily. Treatment will be continued until patient demonstrates clinical benefit at one year, PSA progression, toxicity, or withdrawal. Treatment will be continued after one year if patient demonstrates continued clinical benefit.
Detailed Description
The study will be a national, multicentre, open-label, phase II trial. Patients who have a rising PSA on MAB with bicalutamide 50 mg daily will be dose escalated to MAB with 150 mg bicalutamide daily. Subjects will receive trial treatment for 12 months, or until disease progression, unacceptable toxicity or withdrawal of consent. Open label treatment will be offered thereafter if the subject demonstrates clinical benefit at the end of one year.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Provision of written informed consent.
- •Men, over 18 years of age, with histologically-confirmed prostate cancer
- •Treatment with Zoladex (goserelin acetate) for greater than 3 months prior to Day 1
- •Serum testosterone level < 50 ng/ml
- •Current treatment with bicalutamide 50 mg daily.**
- •Two consecutive rises in PSA above a nadir value, with the absolute value of the latest PSA > 2.0 ng/ml.
- •Highest PSA level no greater than or equal to 30 ng/ml.
- •Life expectancy of greater than 1 year -
Exclusion Criteria
- •Patients may not have received prolonged anti-androgen therapy other than with bicalutamide. Patients who have received short term (2 months or less) non-steroidal anti-androgen therapy with an agent other than bicalutamide to block flare are not excluded.*
- •PSA level greater than 30 ng/ml.
- •In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease which would make it undesirable for the patient to participate in the trial.
- •Subjects who have received prior chemotherapy.
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.
- •Absolute neutrophil count less than 1.5 x 109/L or platelets less than 100 x 109/L.
- •Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULRR.
- •Serum creatinine greater than 1.5 times -
Outcomes
Primary Outcomes
Doubling of PSA
Time Frame: one year
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerProstate CancerNCT01414283Progenics Pharmaceuticals, Inc.52
Recruiting
Phase 2
Phase II Dutasteride in Combination With CAB vs CAB in SDCSalivary Duct CarcinomaNCT05513365Radboud University Medical Center26
Active, not recruiting
Phase 2
A study to investigate whether a combined Positron emission tomography (PET) and computerised tomography (CT) scan which utilises a tracer called Prostate Specific Membrane Antigen (PSMA) - a substance expressed by prostate cancer cells - can be used to better identify locally recurrent prostate cancer in men with a rising Prostate Specific Antigen (PSA) following radical prostatectomy. The study will then measure the impact of early salvage radiation therapy using advanced localisation techniques on patient survival, clinical toxicity, health related quality of life and prostate cancer-specific quality of life.Recurrent prostate cancerCancer - ProstateACTRN12615001183572Icon Cancer Foundation110
Recruiting
Not Applicable
Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia;Benign Prostatic HyperplasiaNCT06601179EDAP TMS S.A.100
Terminated
Phase 2
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate CancerProstate CancerProstatic NeoplasmsNCT02362451National Cancer Institute (NCI)7